Skip to main content
. 2020 Dec 4;10:21280. doi: 10.1038/s41598-020-77978-z

Figure 3.

Figure 3

BR103354 acutely reduces blood glucose levels via FAP inhibition in ob/ob mice. 8-week-old ob/ob mice (n = 5–9/group) were treated with BR103354 or vehicle before 15 min i.p. treatment of hFGF21. Blood was collected at the indicated time points. (a) Nonfasting blood glucose levels were measured at the indicated time points. AUC values are shown for comparison between treatment groups. (b) Plasma FAP activity was measured by fluorometric assay using AMC substrate. (c) Plasma intact hFGF21 levels were measured using ELISA kit at 1, 3, 6, and 9 h. All data are the means ± S.D. *P < 0.05, **P < 0.01 and *** P < 0.001 vs. vehicle group.